Composite Inflammatory Biomarker Linked to Dementia Risk
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, July 21, 2023 -- Higher levels of a composite inflammatory biomarker are associated with an increased subsequent risk for dementia, according to a study published online July 19 in PLOS ONE.
Krisztina Mekli, Ph.D., from the Cathie Marsh Institute for Social Research at the University of Manchester in the United Kingdom, and colleagues examined the association between a composite inflammatory biomarker and cognitive performance measures across five domains measured concurrently and four to 13 years later in a population-based cohort of 500,000 people. In the initially dementia-free sample, the same biomarker's association with dementia diagnosis three to 11 years later was examined.
Comparing the highest with the lowest quartile of the biomarker, the researchers identified small but significant associations between elevated biomarker levels and worsened cognitive performance at baseline for four cognitive tasks (prospective memory, fluid intelligence, reaction time, and numeric memory). For one measure (pairs matching), higher biomarker levels were associated with fewer errors. The fourth quartiles of the baseline biomarker levels were significantly associated with cognitive task scores assessed years later, except for the pairs matching test. The highest versus the lowest biomarker quartile was significantly associated with increased dementia risk (hazard ratio, 1.349; 95 percent confidence level, 1.215 to 1.498; P < 0.001). Probable differences in the association with the highest biomarker quartile were suggested in a case-only analysis between vascular dementia and Alzheimer disease subtypes (odds ratio, 1.483; 95 percent confidence level, 0.991 to 2.220; P = 0.055).
"This association of course does not mean causality, therefore further research is needed to understand and evaluate the potential mechanism," Mekli said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
Emergence of Psychosis in Alzheimer Disease Linked to Elevations in p-tau181
MONDAY, July 1, 2024 -- For individuals with Alzheimer disease (AD), the emergence of psychosis is associated with elevations in levels of plasma tau phosphorylated at threonine...
Cognitive Impairment Delayed With Genetic Variant
THURSDAY, June 20, 2024 -- Cognitive impairment is delayed among persons who are heterozygous for the apolipoprotein E3 Christchurch variant (APOE3Ch), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.